Tenofovir disoproxil (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Tenofovir disoproxil" in English language version.

refsWebsite

Global rank English rank

17nih.gov

4^th place

13doi.org

2^nd place

10web.archive.org

1^st place

3semanticscholar.org

11^th place

8^th place

3fda.gov

447^th place

338^th place

2espacenet.com

800^th place

676^th place

1tga.gov.au

3,984^th place

2,622^nd place

1europa.eu

68^th place

117^th place

1drugs.com

399^th place

333^rd place

1books.google.com

3^rd place

1handle.net

102^nd place

76^th place

1tevapharm.com

low place

1gilead.com

low place

1theconversation.com

928^th place

651^st place

1medlineplus.gov

1,581^st place

1,299^th place

1harvard.edu

18^th place

17^th place

1drugbank.ca

4,294^th place

6,357^th place

1wsj.com

79^th place

65^th place

books.google.com

Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 505. ISBN 9783527607495. Archived from the original on 8 September 2017.

doi.org

Martin P, Lau DT, Nguyen MH, Janssen HL, Dieterich DT, Peters MG, et al. (November 2015). "A Treatment Algorithm for the Management of Chronic Hepatitis B Virus Infection in the United States: 2015 Update". Clinical Gastroenterology and Hepatology. 13 (12): 2071–87.e16. doi:10.1016/j.cgh.2015.07.007. PMID 26188135.
Okwundu CI, Uthman OA, Okoromah CA (July 2012). "Antiretroviral pre-exposure prophylaxis (PrEP) for preventing HIV in high-risk individuals". The Cochrane Database of Systematic Reviews. 7 (7): CD007189. doi:10.1002/14651858.CD007189.pub3. PMC 11324012. PMID 22786505.
Ustianowski A, Arends JE (June 2015). "Tenofovir: What We Have Learnt After 7.5 Million Person-Years of Use". Infectious Diseases and Therapy. 4 (2): 145–57. doi:10.1007/s40121-015-0070-1. PMC 4471058. PMID 26032649.
Morlat P, Vivot A, Vandenhende MA, Dauchy FA, Asselineau J, Déti E, et al. (12 June 2013). "Role of traditional risk factors and antiretroviral drugs in the incidence of chronic kidney disease, ANRS CO3 Aquitaine cohort, France, 2004-2012". PLOS ONE. 8 (6): e66223. Bibcode:2013PLoSO...866223M. doi:10.1371/journal.pone.0066223. PMC 3680439. PMID 23776637.
Delahunty T, Bushman L, Robbins B, Fletcher CV (July 2009). "The simultaneous assay of tenofovir and emtricitabine in plasma using LC/MS/MS and isotopically labeled internal standards". Journal of Chromatography B. 877 (20–21): 1907–14. doi:10.1016/j.jchromb.2009.05.029. PMC 2714254. PMID 19493710.
Kearney BP, Yale K, Shah J, Zhong L, Flaherty JF (2006). "Pharmacokinetics and dosing recommendations of tenofovir disoproxil fumarate in hepatic or renal impairment". Clinical Pharmacokinetics. 45 (11): 1115–24. doi:10.2165/00003088-200645110-00005. PMID 17048975. S2CID 6322957.
Holý A, Rosenberg I (1982). "Preparation of 5'-O-phosphonylmethyl analogues of nucleoside-5'-phosphates, 5'-diphosphates and 5'-triphosphates". Collection of Czechoslovak Chemical Communications. 47 (12): 3447–3463. doi:10.1135/cccc19823447.
Brown Ripin DH, Teager DS, Fortunak J, Basha SM, Bivins N, Boddy CN, et al. (2010). "Process Improvements for the Manufacture of Tenofovir Disoproxil Fumarate at Commercial Scale". Organic Process Research & Development. 14 (5): 1194–1201. doi:10.1021/op1001337.
Houghton SR, Melton J, Fortunak J, Brown Ripin DH, Boddy CN (2010). "Rapid, mild method for phosphonate diester hydrolysis: Development of a one-pot synthesis of tenofovir disoproxil fumarate from tenofovir diethyl ester". Tetrahedron. 66 (41): 8137–8144. doi:10.1016/j.tet.2010.08.037.
Vardanyan R, Hruby V (2016). "34: Antiviral Drugs". Synthesis of Best-Seller Drugs. pp. 714–716. doi:10.1016/B978-0-12-411492-0.00034-1. ISBN 9780124114920. S2CID 75449475.
Deeks SG, Barditch-Crovo P, Lietman PS, Hwang F, Cundy KC, Rooney JF, et al. (September 1998). "Safety, pharmacokinetics, and antiretroviral activity of intravenous 9-[2-(R)-(Phosphonomethoxy)propyl]adenine, a novel anti-human immunodeficiency virus (HIV) therapy, in HIV-infected adults". Antimicrobial Agents and Chemotherapy. 42 (9): 2380–4. doi:10.1128/aac.42.9.2380. PMC 105837. PMID 9736567.
Mouton JP, Cohen K, Maartens G (November 2016). "Key toxicity issues with the WHO-recommended first-line antiretroviral therapy regimen". Expert Review of Clinical Pharmacology. 9 (11): 1493–1503. doi:10.1080/17512433.2016.1221760. PMID 27498720. S2CID 205930751.
Emau P, Jiang Y, Agy MB, Tian B, Bekele G, Tsai CC (November 2006). "Post-exposure prophylaxis for SIV revisited: animal model for HIV prevention". AIDS Research and Therapy. 3: 29. doi:10.1186/1742-6405-3-29. PMC 1687192. PMID 17132170.

drugbank.ca

"Tenofovir". DrugBank. Archived from the original on 8 September 2015.

drugs.com

"Tenofovir Disoproxil Fumarate". The American Society of Health-System Pharmacists. Archived from the original on 30 November 2016. Retrieved 29 November 2016.

espacenet.com

worldwide.espacenet.com

US patent 4808716, Holy A, Rosenberg I, "9-(phosponylmethoxyalkyl) adenines, the method of preparation and utilization thereof", published 1989-02-28, assigned to Czech Academy of Sciences
US 4724233, De Clercq E, Holy A, Rosenberg I, "Therapeutical application of phosphonylmethoxyalkyl adenines"

europa.eu

ema.europa.eu

"Viread EPAR". European Medicines Agency (EMA). 5 February 2002. Retrieved 25 May 2024.

fda.gov

nctr-crs.fda.gov

"FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA. Retrieved 22 October 2023.

fda.gov

Shwiff K. "FDA letter of approval (regarding treatment of hepatitis B)" (PDF). Food and Drug Administration. Archived from the original (PDF) on 25 February 2009.

accessdata.fda.gov

"Drugs@FDA: FDA Approved Drug Products". www.accessdata.fda.gov. Archived from the original on 10 November 2016. Retrieved 9 November 2016.

gilead.com

"Tenofovirdisoproxil Prescribing Information" (PDF). Gilead Sciences, Inc. November 2012. Archived from the original (PDF) on 7 February 2013.

handle.net

hdl.handle.net

World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.

harvard.edu

ui.adsabs.harvard.edu

Morlat P, Vivot A, Vandenhende MA, Dauchy FA, Asselineau J, Déti E, et al. (12 June 2013). "Role of traditional risk factors and antiretroviral drugs in the incidence of chronic kidney disease, ANRS CO3 Aquitaine cohort, France, 2004-2012". PLOS ONE. 8 (6): e66223. Bibcode:2013PLoSO...866223M. doi:10.1371/journal.pone.0066223. PMC 3680439. PMID 23776637.

medlineplus.gov

"Tenofovir: MedlinePlus Drug Information". MedlineP. U.S. National Library of Medicine. Archived from the original on 10 November 2016. Retrieved 9 November 2016.

nih.gov

pubmed.ncbi.nlm.nih.gov

Martin P, Lau DT, Nguyen MH, Janssen HL, Dieterich DT, Peters MG, et al. (November 2015). "A Treatment Algorithm for the Management of Chronic Hepatitis B Virus Infection in the United States: 2015 Update". Clinical Gastroenterology and Hepatology. 13 (12): 2071–87.e16. doi:10.1016/j.cgh.2015.07.007. PMID 26188135.
Okwundu CI, Uthman OA, Okoromah CA (July 2012). "Antiretroviral pre-exposure prophylaxis (PrEP) for preventing HIV in high-risk individuals". The Cochrane Database of Systematic Reviews. 7 (7): CD007189. doi:10.1002/14651858.CD007189.pub3. PMC 11324012. PMID 22786505.
Ustianowski A, Arends JE (June 2015). "Tenofovir: What We Have Learnt After 7.5 Million Person-Years of Use". Infectious Diseases and Therapy. 4 (2): 145–57. doi:10.1007/s40121-015-0070-1. PMC 4471058. PMID 26032649.
Morlat P, Vivot A, Vandenhende MA, Dauchy FA, Asselineau J, Déti E, et al. (12 June 2013). "Role of traditional risk factors and antiretroviral drugs in the incidence of chronic kidney disease, ANRS CO3 Aquitaine cohort, France, 2004-2012". PLOS ONE. 8 (6): e66223. Bibcode:2013PLoSO...866223M. doi:10.1371/journal.pone.0066223. PMC 3680439. PMID 23776637.
Delahunty T, Bushman L, Robbins B, Fletcher CV (July 2009). "The simultaneous assay of tenofovir and emtricitabine in plasma using LC/MS/MS and isotopically labeled internal standards". Journal of Chromatography B. 877 (20–21): 1907–14. doi:10.1016/j.jchromb.2009.05.029. PMC 2714254. PMID 19493710.
Kearney BP, Yale K, Shah J, Zhong L, Flaherty JF (2006). "Pharmacokinetics and dosing recommendations of tenofovir disoproxil fumarate in hepatic or renal impairment". Clinical Pharmacokinetics. 45 (11): 1115–24. doi:10.2165/00003088-200645110-00005. PMID 17048975. S2CID 6322957.
Deeks SG, Barditch-Crovo P, Lietman PS, Hwang F, Cundy KC, Rooney JF, et al. (September 1998). "Safety, pharmacokinetics, and antiretroviral activity of intravenous 9-[2-(R)-(Phosphonomethoxy)propyl]adenine, a novel anti-human immunodeficiency virus (HIV) therapy, in HIV-infected adults". Antimicrobial Agents and Chemotherapy. 42 (9): 2380–4. doi:10.1128/aac.42.9.2380. PMC 105837. PMID 9736567.
Mouton JP, Cohen K, Maartens G (November 2016). "Key toxicity issues with the WHO-recommended first-line antiretroviral therapy regimen". Expert Review of Clinical Pharmacology. 9 (11): 1493–1503. doi:10.1080/17512433.2016.1221760. PMID 27498720. S2CID 205930751.
Emau P, Jiang Y, Agy MB, Tian B, Bekele G, Tsai CC (November 2006). "Post-exposure prophylaxis for SIV revisited: animal model for HIV prevention". AIDS Research and Therapy. 3: 29. doi:10.1186/1742-6405-3-29. PMC 1687192. PMID 17132170.

ncbi.nlm.nih.gov

Okwundu CI, Uthman OA, Okoromah CA (July 2012). "Antiretroviral pre-exposure prophylaxis (PrEP) for preventing HIV in high-risk individuals". The Cochrane Database of Systematic Reviews. 7 (7): CD007189. doi:10.1002/14651858.CD007189.pub3. PMC 11324012. PMID 22786505.
Ustianowski A, Arends JE (June 2015). "Tenofovir: What We Have Learnt After 7.5 Million Person-Years of Use". Infectious Diseases and Therapy. 4 (2): 145–57. doi:10.1007/s40121-015-0070-1. PMC 4471058. PMID 26032649.
Morlat P, Vivot A, Vandenhende MA, Dauchy FA, Asselineau J, Déti E, et al. (12 June 2013). "Role of traditional risk factors and antiretroviral drugs in the incidence of chronic kidney disease, ANRS CO3 Aquitaine cohort, France, 2004-2012". PLOS ONE. 8 (6): e66223. Bibcode:2013PLoSO...866223M. doi:10.1371/journal.pone.0066223. PMC 3680439. PMID 23776637.
Delahunty T, Bushman L, Robbins B, Fletcher CV (July 2009). "The simultaneous assay of tenofovir and emtricitabine in plasma using LC/MS/MS and isotopically labeled internal standards". Journal of Chromatography B. 877 (20–21): 1907–14. doi:10.1016/j.jchromb.2009.05.029. PMC 2714254. PMID 19493710.
Deeks SG, Barditch-Crovo P, Lietman PS, Hwang F, Cundy KC, Rooney JF, et al. (September 1998). "Safety, pharmacokinetics, and antiretroviral activity of intravenous 9-[2-(R)-(Phosphonomethoxy)propyl]adenine, a novel anti-human immunodeficiency virus (HIV) therapy, in HIV-infected adults". Antimicrobial Agents and Chemotherapy. 42 (9): 2380–4. doi:10.1128/aac.42.9.2380. PMC 105837. PMID 9736567.
Emau P, Jiang Y, Agy MB, Tian B, Bekele G, Tsai CC (November 2006). "Post-exposure prophylaxis for SIV revisited: animal model for HIV prevention". AIDS Research and Therapy. 3: 29. doi:10.1186/1742-6405-3-29. PMC 1687192. PMID 17132170.

pubchem.ncbi.nlm.nih.gov

"Stribild". PubChem. U.S. National Library of Medicine. Retrieved 6 February 2022.
"Tenofovir disoproxil". Pubchem. U.S. National Library of Medicine. Retrieved 17 April 2018.

semanticscholar.org

api.semanticscholar.org

Kearney BP, Yale K, Shah J, Zhong L, Flaherty JF (2006). "Pharmacokinetics and dosing recommendations of tenofovir disoproxil fumarate in hepatic or renal impairment". Clinical Pharmacokinetics. 45 (11): 1115–24. doi:10.2165/00003088-200645110-00005. PMID 17048975. S2CID 6322957.
Vardanyan R, Hruby V (2016). "34: Antiviral Drugs". Synthesis of Best-Seller Drugs. pp. 714–716. doi:10.1016/B978-0-12-411492-0.00034-1. ISBN 9780124114920. S2CID 75449475.
Mouton JP, Cohen K, Maartens G (November 2016). "Key toxicity issues with the WHO-recommended first-line antiretroviral therapy regimen". Expert Review of Clinical Pharmacology. 9 (11): 1493–1503. doi:10.1080/17512433.2016.1221760. PMID 27498720. S2CID 205930751.

tevapharm.com

"Teva Announces Exclusive Launch of a Generic version of Viread in the United States". www.tevapharm.com. Archived from the original on 6 November 2018. Retrieved 6 November 2018.

tga.gov.au

"Prescription medicines: registration of new generic medicines and biosimilar medicines, 2017". Therapeutic Goods Administration (TGA). 21 June 2022. Retrieved 30 March 2024.

theconversation.com

Bourke E (14 June 2013). "Preventive drug could reduce HIV transmission among injecting drug users". The Conversation Australia. The Conversation Media Group. Archived from the original on 1 November 2013. Retrieved 17 June 2013.

web.archive.org

"Tenofovir Disoproxil Fumarate". The American Society of Health-System Pharmacists. Archived from the original on 30 November 2016. Retrieved 29 November 2016.
Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 505. ISBN 9783527607495. Archived from the original on 8 September 2017.
"Teva Announces Exclusive Launch of a Generic version of Viread in the United States". www.tevapharm.com. Archived from the original on 6 November 2018. Retrieved 6 November 2018.
"Tenofovirdisoproxil Prescribing Information" (PDF). Gilead Sciences, Inc. November 2012. Archived from the original (PDF) on 7 February 2013.
Bourke E (14 June 2013). "Preventive drug could reduce HIV transmission among injecting drug users". The Conversation Australia. The Conversation Media Group. Archived from the original on 1 November 2013. Retrieved 17 June 2013.
"Tenofovir: MedlinePlus Drug Information". MedlineP. U.S. National Library of Medicine. Archived from the original on 10 November 2016. Retrieved 9 November 2016.
"Tenofovir". DrugBank. Archived from the original on 8 September 2015.
Shwiff K. "FDA letter of approval (regarding treatment of hepatitis B)" (PDF). Food and Drug Administration. Archived from the original (PDF) on 25 February 2009.
Shwiff K (11 August 2008). "FDA Clears Viread for Hepatitis B". The Wall Street Journal. Dow Jones & Company, Inc. Archived from the original on 8 September 2017.
"Drugs@FDA: FDA Approved Drug Products". www.accessdata.fda.gov. Archived from the original on 10 November 2016. Retrieved 9 November 2016.

wsj.com

Shwiff K (11 August 2008). "FDA Clears Viread for Hepatitis B". The Wall Street Journal. Dow Jones & Company, Inc. Archived from the original on 8 September 2017.